Story

Viking Therapeutics Named Top Biotech Pick by Cantor Fitzgerald on Obesity Drug Hopes

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Viking Therapeutics Named Top Biotech Pick by Cantor Fitzgerald on Obesity Drug Hopes
Text size
Background

Cantor Fitzgerald has initiated coverage on Viking Therapeutics (NASDAQ: VKTX), designating the company as a top pick in the biotechnology sector. The investment firm assigned an Overweight rating and set a price target of $111 per share, signaling significant upside from its current trading levels.

Analyst's Thesis

The bullish outlook from Cantor is primarily driven by the potential of Viking's lead drug candidate, VK2735, an injectable treatment for obesity. The analyst note highlighted the drug's promising clinical data, which suggests a competitive profile in the rapidly expanding market for weight-loss therapies.

According to Cantor, VK2735's efficacy and safety profile could position it as a strong contender against established treatments. The firm believes the market is currently underappreciating the commercial potential of Viking's pipeline, presenting a favorable risk/reward opportunity for investors.

Competitive Landscape

Viking Therapeutics is entering a market dominated by pharmaceutical giants Novo Nordisk and Eli Lilly, whose GLP-1 agonist drugs Wegovy and Zepbound have seen massive commercial success. These treatments have set a high bar for both efficacy and safety in the obesity space.

Sample IUX Markets – In-articleAd

For Viking to capture market share, VK2735 will need to demonstrate clear advantages, such as superior weight loss, a better side-effect profile, or more convenient dosing. Investors will be closely watching upcoming clinical trial results to assess its potential to differentiate itself from the competition.

What It Means for Investors

The initiation of coverage provides a new, positive data point for investors evaluating Viking's stock. The $111 price target suggests that Cantor's model anticipates successful clinical development and a significant share of the multi-billion dollar obesity market.

However, as with any clinical-stage biotechnology company, investing in Viking carries inherent risks. The stock's performance will be heavily dependent on future trial outcomes and subsequent regulatory decisions from agencies like the U.S. Food and Drug Administration (FDA).

Read next

More on Stocks
Back to latest news

LATEST